Comparison of 12% Ammonium Lactate and 10% Urea Cream in Geriatric With Xerosis Cutis

First Evaluation of Specified Symptom Sum Score (SRRC)

System with grading of scaliness, roughness, redness, and cracks with score ranges from 0-12 because the redness and cracks scores were limited to 2. Performed before therapy.

Time frame: initial visit (day 1)

Second Evaluation of Specified Symptom Sum Score (SRRC)

System with grading of scaliness, roughness, redness, and cracks with score ranges from 0-12 because the redness and cracks scores were limited to 2. Performed during therapy.

Time frame: Change of SSRC at day 15 from initial visit

Third Evaluation of Specified Symptom Sum Score (SRRC)

System with grading of scaliness, roughness, redness, and cracks with score ranges from 0-12 because the redness and cracks scores were limited to 2. Performed during therapy.

Time frame: Change of SSRC at day 29 from initial visit

Fourth Evaluation of Specified Symptom Sum Score (SRRC)

System with grading of scaliness, roughness, redness, and cracks with score ranges from 0-12 because the redness and cracks scores were limited to 2. Performed after 1 week of therapy discontinuation

Time frame: Change of SSRC at day 36

First Evaluation of Skin Capacitance (SCap)

Assess the skin barrier homeostasis condition using Corneometer® CM 825 (Courage - Khazaka, Germany). Performed before therapy.

Time frame: Performed at initial visit (day-1)

Second Evaluation of Skin Capacitance (SCap)

Assess the skin barrier homeostasis condition using Corneometer® CM 825 (Courage - Khazaka, Germany). Performed during therapy.

Time frame: Change of SCap at day-15

Third Evaluation of Skin Capacitance (SCap)

Assess the skin barrier homeostasis condition using Corneometer® CM 825 (Courage - Khazaka, Germany). Performed during therapy.

Time frame: Change of SCap at day-29

Fourth Evaluation of Skin Capacitance (SCap)

Assess the skin barrier homeostasis condition using Corneometer® CM 825 (Courage - Khazaka, Germany). Performed after 1 week of therapy discontinuation

Time frame: Change of SCap at day-36

First Evaluation of Transepidermal Water Loss (TEWL)

Assess the skin barrier homeostasis condition using Tewameter® TM300 before therapy.

Time frame: Performed at initial visit (day-1)

Second Evaluation of Transepidermal Water Loss (TEWL)

Assess the skin barrier homeostasis condition using Tewameter® TM300. Performed during therapy.

Time frame: Change of TEWL at day-15 from initial visit

Third Evaluation of Transepidermal Water Loss (TEWL)

Assess the skin barrier homeostasis condition using Tewameter® TM300. Performed during therapy.

Time frame: Change of TEWL at day-29 from initial visit

Fourth Evaluation of Transepidermal Water Loss (TEWL)

Assess the skin barrier homeostasis condition using Tewameter® TM300. Performed after 1 week of therapy discontinuation.

Time frame: Change of TEWL at day-36 from initial visit

First Side Effect Evaluation

Subjective by the presence of contact dermatitis, folliculitis, and miliaria; objective by complaints of pruritus, sore, or stinging.

Time frame: Performed at 2 weeks after therapy (day-15)

Second Side Effect Evaluation

Subjective by the presence of contact dermatitis, folliculitis, and miliaria; objective by complaints of pruritus, sore, or stinging.

Time frame: Performed at day-29 (4 weeks after therapy)

Third Side Effect Evaluation

Subjective by the presence of contact dermatitis, folliculitis, and miliaria; objective by complaints of pruritus, sore, or stinging. Performed after 1 week of therapy discontinuation

Time frame: Performed at day-36 (5 weeks after therapy)